In the past week the FDA recommended the approval of evolocumab and alirocumab injections. Our authors and experts have talked about the exciting benefits of PCSK9 inhibitors, as well as their barriers of cost. Do ezetimibe and PCSK9 inhibitors target different types of patient populations that would benefit more from one drug over the other? Could these monoclonal antibodies eventually be combined with ezetimibe to synergistically reduce LDL cholesterol levels? What are your thoughts about the direction of non-statin therapy research?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.